An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis Across Phase III and Long-Term Extension Studies With Comparison to Real-World Observational Data

Drug Safety - United Kingdom
doi 10.1007/s40264-020-00904-9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

SAT0439 Integrated Safety Summary of Tofacitinib in Psoriatic Arthritis Clinical Studies

2017English

Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Chronic Plaque Psoriasis: Long-Term Efficacy and Safety Results From 2 Randomized Phase-Iii Studies and 1 Open-Label Long-Term Extension Study

Journal of the American Academy of Dermatology
Dermatology
2016English

Tofacitinib: Efficiency and Safety in Long-Term Use

Medical Council
2019English

Tofacitinib for the Treatment of Psoriasis and Psoriatic Arthritis

Expert Review of Clinical Immunology
AllergyImmunology
2018English

Real-World Burden of Comorbidities in US Patients With Psoriatic Arthritis

RMD Open
RheumatologyAllergyImmunology
2017English

Long-Term Survival of Methotrexate in Psoriatic Arthritis

Reumatismo
Rheumatology
2011English

Long-Term Safety and Tolerability of Oral Tofacitinib in Patients With Crohn’s Disease: Results From a Phase 2, Open-Label, 48-Week Extension Study

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Real-World Data on Secukinumab Use for Psoriatic Arthritis and Ankylosing Spondylitis

Therapeutic Advances in Musculoskeletal Disease
RheumatologyOrthopedicsSports Medicine
2019English

Safety and Efficacy of Tofacitinib for Up to 9.5 Years in the Treatment of Rheumatoid Arthritis: Final Results of a Global, Open-Label, Long-Term Extension Study

Arthritis Research & Therapy
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy